CDA | Evidence Driven
CDA | Evidence Driven

lecanemab

Details

Generic Name:
lecanemab
Project Status:
Pending
Therapeutic Area:
Alzheimer’s disease
Manufacturer:
Eisai Canada
Call for patient/clinician input open:
Brand Name:
Leqembi
Project Line:
Reimbursement Review
Project Number:
SR0822-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Lecanemab is a disease-modifying treatment for adult patients with Alzheimer’s disease. Treatment with lecanemab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease. Patients must have documented presence of amyloid beta pathology. Lecanemab should be prescribed by clinicians with expertise in diagnosing, managing and treating patients with mild cognitive impairment or mild dementia stage of disease (early AD).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Lecanemab is indicated as a disease-modifying treatment in adult patients with Alzheimer’s disease. Treatment with lecanemab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : April 25, 2024